Correlation between myocardial enzyme serum levels and markers of inflammation with severity of coronary artery disease and Gensini score: A hospital-based, prospective study in Greek patients

Clinical Interventions in Aging

Volumn 3, Issue 4, 2008, Pages 699-710

  Peppes, Vasileios ^a,b   Rammos, George ^a   Manios, Efstathios ^a   Koroboki, Eleni ^a   Rokas, Stylianos ^a   Zakopoulos, Nikolaos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Coronary angiography; Coronary artery disease; Inflammation; Myocardial enzymes

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE; FIBRINOGEN; LACTATE DEHYDROGENASE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; GENSINI SCORE; GREECE; HEART INFARCTION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; GREECE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 60749109886     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Anderson KM, Castelli WP, Levy D. 1987. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA, 257:2176-80.
2. Antman EM, Anbe DT, Armstrong PW, et al. for the American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society. 2004. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation, 110:e82-e293.
3. Berk BC, Weintraub WS, Alexander RW. 1990. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol, 65:168-72.
4. Biasucci LM, CDC, AHA. 2004. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation, 110:e560-e567.
5. Blake GJ, Ridker PM. 2003. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol, 41(4 Suppl S):375-42S.
6. Brunetti ND, Troccoli R, Correale M, et al. 2006. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol, 109:248-56.
7. Castelli WP, Garrison RJ, Wilson PW, et al. 1986. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA, 256:2835-8.
8. Chambers JC, Eda S, Bassett P, et al. 2001. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation, 104:145-50.
9. Choi HK, Curhan G. 2007. Independent impact of gout on mortality and risk for coronary heart disease. Circulation, 116:894-900.
10. Cockerill GW, Rye KA, Gamble JR, et al. 1995. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol, 15:1987-94.
11. Colditz GA, Rimm EB, Giovannucci E, et al. 1991. A prospective study of parental history of myocardial infarction and coronary artery disease in men. Am J Cardiol, 67:933-8
12. Conti CR. 1977. Coronary arteriography. Circulation, 55:227-37.
13. Danesh J, Muir J, Wong Y, et al. 1999. Risk factors for coronary heart disease and acute-phase proteins: A population-based study. Eur Heart J, 20:954-9.
14. Eidelman RS, Hennekens CH. 2003. Fibrinogen: a predictor of stroke and marker of atherosclerosis. Eur Heart J, 24:499-500.
15. Erikssen G, Liestol K, Bjornholt JV, et al. 2000. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. Eur Heart J, 21:1614-20.
16. Erikssen J, Mundal R. 1982. The non-infarct patient with coronary artery disease: can a high risk group be identified? Ann NY Acad Sci, 382:438-9.
17. Fox CS, Coady S, Sorlie PD, et al. 2007. Increasing cardiovascular disease burden due to diabetes mellitus. The Framingham Heart Study. Circulation, 115:1544-50.
18. Gensini GG. 1980. Chapter 10: Coronary arteriography. Pp. 308-62. In: Braunwald E (ed). Heart Disease. Philadelphia: WB Saunders Company.
19. Gensini GG. 1983. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 51:606.
20. Gotto AM Jr. 1998. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol, 82(9A):22Q-25Q.
21. Hayashi M, Fujimoto K, Urushibata K, et al. 2003. Nocturnal oxygen desaturation correlates with the severity of coronary atherosclerosis in coronary artery disease. Chest, 124:936-41.
22. [ICSH] International Committee for Standardization in Hematology (Expert Panel on Blood Rheology). 1988. Guidelines on selection of laboratory tests for monitoring the acute phase response. J Clin Pathol, 41:1203-12.
23. Jenkins DC, Rosenman RH, Zyzanski SJ. 1968. Cigarette smoking: Its relationship to coronary heart disease and related risk factors in the Western Collaborative Group Study. Circulation, 38:1140-55.
24. Jia EZ, Yang ZJ, Yuan B, et al. 2005. Relationship between leukocyte count and angiographical characteristics of coronary atherosclerosis. Acta Pharmacologica Sinica, 26:1057-62.
25. Kannel WB. 1996. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA, 275:1571-6.
26. Kannel WB, McGee DL. 1979. Diabetes and cardiovascular disease. The Framingham study. JAMA, 241:2035-8.
27. Law MR, Wald NJ, Wu T, et al. 1994a. Systematic underestimation of association between serum cholesterol concentration and ischemic heart disease in observational studies: data from the BUPA study. BMJ, 308:363-6.
28. Law MR, Wald NJ, Thompson SG. 1994b. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease. BMJ, 308:367-73.
29. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. 2004. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. A prospective study of parents and offspring. JAMA, 291:2204-11.
30. Madjid M, Awan I, Willerson JT, et al. 2004. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol, 44:1945-56.
31. Mannila MN. 2006. Fibrinogen and susceptibility to myocardial infarction. Stockholm: Karolinska University Press.
32. Martin MJ, Hulley SB, Browner WS, et al. 1986. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet, 2(8513):933-6.
33. Meade TO, Mellows S, Brozovic M, et al. 1986. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet, 2(8506):533-7.
34. Melanson SE, Tanasijevic MJ, Jarolim P, et al. 2007. Cardiac troponin assays: a view from the clinical chemistry laboratory. Circulation, 116:e501-4.
35. Mendall MA, Strachan DP, Butland BK, et al. 2000. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J, 21:1584-90.
36. Möckel M, Störk T, Heller G Jr, et al. 1998. Troponin T in patients with low grade or atypical Angina. Identification of a high risk group for short- and long-term cardiovascular events. Eur Heart J, 19:1802-7.
37. Morrow DA, Cannon CP, Jesse RL, et al. 2007. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem, 53:552-74.
38. Mosca L, Collins P, Herrington DM, et al. 1997. American Heart Association. Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association. Circulation, 96:2468-82.
39. Neumann FJ, Ott I, Gawaz M, et al. 1995. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation, 92:748-55.
40. Omran MT, Asadollahi S. 2007. The measurement of serum fibrinogen levels in patients with acute coronary syndrome. Saudi Med J, 28:1350-2.
41. Pai J, Pischon T, Ma J, et al. 2004. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med, 351:2599-610.
42. Panteghini M. 2004. Role and importance of biochemical markers in clinical cardiology. Eur Heart J, 25:1187-96.
43. Pasceri V, Willerson JT, Yeh ET. 2000. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 102:2165-68.
44. Pasceri V, Cheng JS, Willerson JT, et al. 2001. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation, 103:2531-4.
45. Pearson TA, Mensah GA, Alexander RW, et al.2003. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation, 107:499-511.
46. Pekkanen J, Linn S, Heiss G, et al. 1990. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med, 322:1700-7.
47. Ridker PM, Hennekens CH, Buring JE, et al. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 342:836-43.
48. Ross R. 1999. Atherosclerosis - an inflammatory disease. N Engl J Med, 340:115-26.
49. Sampietro T, Bigazzi F, Dal Pino B, et al. 2002. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia. A proinflammatory condition? Circulation, 105:11-4.
50. Scanlon PJ, Faxon DP, Audet AM, et al. 1999. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol, 33:1756-824.
51. Sepulveda JL, Mehta JL. 2005. C-reactive protein and cardiovascular disease: a critical appraisal. Curr Opin Cardiol, 20:407-16.
52. Sun YH, Yang YJ, Pei WD, et al. 2006. Patients with low high-density lipoprotein-cholesterol or smoking are more likely to develop myocardial infarction among subjects with a visible lesion or stenosis in coronary artery. Circ J, 70:1602-5.
53. Tarchalski J, Guzik P, Wysocki H. 2003. Correlation between the extent of coronary atherosclerosis and lipid profile. Mol Cell Biochem, 246:25-30.
54. Tedgui A, Mallat Z. 2001. Anti-inflammatory mechanisms in the vascular wall. Circ Res, 88:877-87.
55. Vasan RS, Massaro JM, Wilson PWF, et al. 2002. Antecedent blood pressure and risk of cardiovascular disease. The Framingham Heart Study. Circulation, 105:48-53.
56. Venugopal S.K. Devaraj S, Yuhanna I, et al. 2002. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation, 106:1439-41.
57. Wadham C, Albanese N, Roberts J, et al. 2004. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation, 109:2116-22.
58. Wilhelmsen L, Svärdsudd K, Kotsan-Bengtsen K, et al. 1984. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med, 311:501-5.
59. Yasue H, Hirai N, Mizuno Y, et al. 2006. Low-grade inflammation, thrombogenicity, and atherogenic lipid profile in cigarette smokers. Circ J, 70:8-13.